Apellis Pharmaceuticals (APLS) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $1.67.
- Apellis Pharmaceuticals' EPS (Weighted Average and Diluted) rose 46304.35% to $1.67 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.31, marking a year-over-year increase of 11534.65%. This contributed to the annual value of -$1.6 for FY2024, which is 6411.2% up from last year.
- Apellis Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to $1.67 in Q3 2025, which was up 46304.35% from -$0.33 recorded in Q2 2025.
- Apellis Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at $1.67 for Q3 2025, and its period low was -$2.72 during Q2 2021.
- In the last 5 years, Apellis Pharmaceuticals' EPS (Weighted Average and Diluted) had a median value of -$1.1 in 2023 and averaged -$1.01.
- In the last 5 years, Apellis Pharmaceuticals' EPS (Weighted Average and Diluted) tumbled by 19527.39% in 2021 and then skyrocketed by 46304.35% in 2025.
- Apellis Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$1.53 in 2021, then rose by 1.96% to -$1.5 in 2022, then surged by 52.0% to -$0.72 in 2023, then soared by 59.28% to -$0.29 in 2024, then skyrocketed by 669.58% to $1.67 in 2025.
- Its EPS (Weighted Average and Diluted) stands at $1.67 for Q3 2025, versus -$0.33 for Q2 2025 and -$0.74 for Q1 2025.